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Pharmacogenomics uses information about a person’s genetic makeup to choose 
the drugs dosage regimens that are likely to work best for that particular person. 
The genomic research has changed the “one size fits all” approach and opened the 
door to more personalized approaches that consider individual genetic makeup tend 
to enhance the efficacy and safety of drugs; thus saving time and money. Patient 
DNA influences multiple steps in which the drugs interact with the body and where 
will the drug act in the body. Genetic makeup-based prescription, design, and 
implementation of therapy do not only improve the outcome of treatments, but 
also reduce the risk of toxicity and other adverse events. The aim of the chapter is 
to explore the documented pharmacogenomics of essential as per pharmacoge-
nomic biomarkers in drug labeling; and suggest efficacy and safety modifications. 
Polymorphism of drug metabolizing enzymes has the greatest effect on inter indi-
vidual variability of drug response; affecting the response of individuals to drugs 
used in the treatment of diseases. Also, genetic deficiency of some enzymes limits 
effectiveness of drugs in treating concerned diseases. Gene testing prior to initiat-
ing concerned treatment is the best clinical practice that to enhance the efficacy and 
safety of drugs.
Keywords: Pharmacogenomics, 21st WHO essential medicines “core” list,  
genetic testing
1. Introduction
The National Institute of General Medical Sciences define pharmacogenomics 
(or pharmacogenetics) as is a field of research that studies how a person’s genes 
affect how he or she responds to medications [1]. The Centers for Disease Control 
(CDC) have regarded pharmacogenomics as an important example of precision 
medicine whereby medical treatment is tailored for each patient; based on indi-
vidual genetic makeup [2]. The National Human Genome Research Institute further 
contended that Pharmacogenomics uses information about a person’s genetic 
makeup (or genome) to choose the drugs and dosages that are likely to work best 
for that particular person. The field is an amalgam of two fields; namely pharma-
cology (the science of how drugs work) and genomics (the science of the human 
genome) [3].
The long term goal of pharmacogenomics is to help doctors select the drugs and 
dosage regimens best suited for each person. This is done in order to eliminate the 
ancient perspective that drugs have been developed with the idea that each drug 
works pretty much the same in everybody. But genomic research has changed that 
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“one size fits all” approach and opened the door to more personalized approaches 
to using and developing drugs [3]. The approaches that consider individual 
genetic makeup tend to enhance the efficacy and safety of drugs; thus saving time 
and money.
The World Health Organization (WHO) defines essential medicines as those 
medicines that satisfy the priority health care needs of the population and are 
selected with due regard to evidence on efficacy and safety, and comparative cost-
effectiveness. Essential medicines are intended to be available within the context 
of a well-functioning healthcare system at all times in adequate quantities, in the 
appropriate dosage forms, with assured quality and adequate information, and at a 
cost the individual and the community can afford [4]. Since 1977, WHO developed 
a model Essential Medicines List (EML) that could be adapted by member states 
in order to keep essential medicines up to date in a healthcare system. The current 
version of the list is the 21st WHO EML updated in June 2019 [5].
With the background given above about pharmacogenomics and essential 
medicines, the aim of the chapter is to explore the documented pharmacogenomics 
of essential medicines “core list” of 21st WHO EML as per United States Food and 
Drug Administration (USFDA) Table of Pharmacogenomic Biomarkers in Drug 
Labeling updated in June 2020 [6]; and suggest therapeutic modifications that can 
be done in order to enhance efficacy and safety of essential medicines.
1.1 How pharmacogenomics work
Patient DNA influences multiple steps in which the drugs interact with the body 
and where will the drug act in the body.
1.1.1 Drug receptors
In order to interact with the body, most drugs associate with cellular molecules 
called receptors. The receptor is the component of a cell or organism that interacts 
with a drug and initiates the chain of events leading to the drug’s observed effects 
[7]. The patient genetic makeup (DNA) determines the type of receptors to have 
and their quantities, which can affect the response to the drug. As illustrated in 
Figure 1 below, some individuals might need a higher or lower amount of the drug 
than most people or a different drug.
A living example of this kind of a scenario is the case of Trastuzumab emtansine 
(T-DM1) and breast cancer tumors with or without human epidermal growth factor 
Figure 1. 
Patient response relative to drug-receptor interactions and receptor availability.
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receptor 2 (HER2) receptor. Some breast cancers make too much HER2 and this 
extra HER2 helps the cancer develop and spread. T-DM1 has shown potential activ-
ity in this subset of patients in small clinical series because it works by attaching 
to HER2 on cancerous cells and killing them. In terms of receptor availability, this 
mean if a patient tumor has a high amount of HER2 (HER2 positive), the doctor 
may prescribe T-DM1; but if the tumor does not have enough HER2 (HER2 nega-
tive), T-DM1 will not work for such a patient [8].
1.1.2 Drug uptake
Some drugs have receptor inside the cells or receptor binding sites on the inside 
part of the target cell. Therefore these drugs need to be actively taken into the tissues 
and cells in which they act. The ability and the rate of a cell to uptake the drug is deter-
mined by that cell’s genetic makeup. The genetic makeup can also affect how quickly 
some drugs are removed from the cells in which they act and if drugs are pumped out 
from the cell too quickly, they might not have time to elicit observed effect. Decreased 
uptake can mean that the drug does not work as well and can cause it to build up in 
other parts of your body, which can cause problems (refer to Figure 2 below) [2].
For instance, in the treatment of dyslipidaemia (high cholesterol and/or fats 
levels in blood) drugs called statins are used to reduce cholesterol from the liver 
and these drugs are known to cause muscle problems. Intake of simvastatin for 
the disease requires that the drug be taken up into the liver by the protein encoded 
by SLCO1B1 gene. Some people have a specific change in this gene that causes less 
of simvastatin to be taken into the liver. Intake of high doses of simvastatin could 
lead to build up of the drug in the muscles, causing muscle weakness and pain. 
Therefore prior to prescribing simvastatin, genetic testing of SLCO1B1 gene to 
check if simvastatin is the best statin for use is key [9].
1.1.3 Drug breakdown
Genetic factors that influence enzyme levels account for differences in drug 
breakdown, giving rise to “genetic polymorphisms” in drug metabolism. If the 
patient breaks the drug down more quickly than most people, the body gets rid of 
the drug faster and the patient might need more of the drug or a different drug; 
lesser if the body breaks the drug down more slowly as illustrated in Figure 3 below.
Metabolic reactions mediated by P450 phase I enzymes typically modify 
functional groups (−OH, −SH, −NH2, −OCH3) of endogenous and exogenous 
compounds (drugs), resulting in an alteration of the biological activity of the com-
pound. Phase I enzymes are involved in the metabolism of over 75% of prescription 
drugs; therefore, polymorphisms in these enzymes may significantly affect blood 
levels, which in turn may alter response to many drugs [10].
Figure 2. 
Differences in drug uptake and potential accumulation leading to toxicity.
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1.2 The impact of pharmacogenomics on medical treatment
Pharmacogenomics provides a better understanding the reasons behind the 
differing responses of a drug by individuals. The discovery of genetic variation and 
its associated response variation to a drug, provide the basis for recommending a 
drug regimen to an individual patient. Genetic makeup-based prescription, design, 
and implementation of therapy do not only improve the outcome of treatments, but 
also reduce the risk of toxicity and other adverse events. Therefore genetic testing 
promotes a better understanding of individual variations and their effect on drug 
response, metabolism excretion, toxicity and this will replace the trial-and-error 
approach of treatment which is a common practice [11]. Pharmacogenomics  
promote personalized medicine instead.
1.3 Biomarkers and “core” essential drugs
The Table 1 below is a summary of “core list”essential medicines identified from 
the 21st WHO EML updated in June 2019 [5] presented against the corresponding 
biomarkers and therapeutic areas from the USFDA Table of Pharmacogenomic 
Biomarkers in Drug Labeling updated in June 2020 [6].
2. Clinical pharmacogenomics of the biomarkers and implicated drugs
2.1 Cytochrome p450 isozymes
Polymorphic cytochrome P450 isozymes, CYP2C9, CYP2C19 and CYP2D6 
in particular, mediate approximately 40% of P450-oxidative drug metabolism, 
which makes drug dosing problematic. Generally four genetically different types of 
individuals have been identified, namely:
1. Poor metabolizers (PMs), who lack the functional enzyme;
2. Intermediary metabolizers (IMs), who are heterozygous for one deficient allele 
or carry two alleles that cause reduced enxyme activity;
3. Extensive metabolizers (EMs), who have two normal alleles; and
4. Ultrarapid metabolizers (UMs), who have two have multiple gene copies, a 
trait that is dominantly inherited.
Figure 3. 
Rates of drug metabolism.
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Biomarker Drug (s) Therapeutic area
CYB5R Metoclopramide Gastroenterology
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Polymorphism of cytochrome P450 metabolizing enzymes has the greatest 
effect on inter individual variability of drug response. These polymorphisms affect 
the response of individuals to drugs used in the treatment of diseases not limited 
to cardiology, hematology, neurology, psychiatry, gynaecology, gastroenterology, 
anaesthesiology and infectious diseases [12].
The effect on CYP2C9 on warfarin dosing has been evident. Individuals who 
are heterozygous for a *2 allele and *3 allele of CYP2C9 would require, on average, 
a 21% and 34% lower daily dose of warfarin for maintenance, respectively; than 
homozygous wild-type patients, and individuals who are homozygous for the *2 
allele or the *3 allele require a 60–75% lower dose of warfarin than homozygous 
wild-type patients [13].
CYP2D6 is responsible for the metabolism of most psychoactive drugs, includ-
ing the tricyclic antidepressants and the dosage required corresponds closely with 
the CYP2D6 phenotype. The kinetics of nortriptyline is dependent on the number 
of active CYP2D6 genes and the dosage required to reach the same plasma levels 
varies from 30 to 50 mg in PMs to 500 mg in UMs [14].
The majority of phenytoin metabolism is done by CYP2C9 and effective dosing 
of phenytoin is highly linked to the CYP2C9 genotype. Several examples of adverse 
effects of phenytoin, including CNS intoxication and other neurological symptoms, 
have been described in patients with defective CYP2C9 alleles following phenytoin 
treatment [15].
Dosing with proton pump inhibitors to reach a therapeutic drug plasma concen-
tration highly depends on the CYP2C19 phenotype. A study conducted using a low 
dose omeprazole (20 mg) to treat ulcers, revealed very low cure rates in EMs (25%), 
higher in IMs (50%) and complete in PMs (100%), illustrating the necessity of 
higher plasma levels for effective treatment [16].
CYP2B6 polymorphisms can affect the pharmacokinetics and therapeutic 
outcome of anti-HIV agents, such as efavirenz, which is a substrate of CYP2B6. 
The CYP2B6*6 allele harboring the 516G > T (Q172H) and 785A > G (K262R) was 





Nonspecific (Genetic Susceptibility 
to Malignant Hyperthermia)
Isoflurane Anaesthesiology




POLG Valproic acid Neurology
PROC1 Warfarin Hematology
Estradiol Gynaecology
SERPINC1 (Antithrombin III) Progesterone Gynaecology
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significantly associated with a pronounced decrease in CYP2B6 expression and 
activity. CYP2B6 genetic polymorphisms markedly influence the metabolism of 
efavirenz in human liver microsomes [17].
2.2 Cytochrome b5 reductases (CYB5R)
Patients with NADH-cytochrome b5 reductase deficiency, encoded by CYB5R1, 
CYB5R2, CYB5R3 and CYB5R4 genes, are at an increased risk of developing methe-
moglobinemia and/or sulfhemoglobinemia when metoclopramide is administered. 
Additionally, neonates have reduced levels of NADH-cytochrome b5 reductase and 
prolonged drug clearance, and therefore are also more susceptible to methemoglo-
binemia [18].
2.3 Non-cytochrome p450 enzymes
2.3.1 Vitamin K epoxide reductase complex subunit 1 (VKORC1)
The wide variation in warfarin dose highlights the heterogeneity amongst 
patients in therapeutic response to warfarin. A study conducted by Harrington et al. 
demonstrated that a heterozygous 196G → A transition that predicted a Valine-66 
Methionine substitution in the VKORC1 polypeptide is the cause of warfarin 
resistance [19]. VKORC1 polymorphisms can significantly changes pharmacody-
namics and maintenance dose requirements for warfarin. Patients with the 1639A 
(rs992323) and 1173 T (rs9934438) allele require a lower warfarin dose compared 
with patients with 9041A (rs7294) allele rather need a higher warfarin dose. 
Incorporating VKORC1 and CYP2C9 genotype information into the warfarin dosing 
equation holds great promise to select the optimal dose for the individual patient at 
the start of warfarin therapy [20].
2.3.2 Glucose-6-Phosphate Dehydrogenase (G6PD)
G6PD deficiency is an X-linked genetic disorder with 187 known allelic 
mutations. G6PD is a critical enzyme in the pentose phosphate pathway. G6PD 
deficiency exhibits diminished activity in these patients, leading to inadequate 
production of protective intracellular thiols during oxidative stress. The deficiency 
makes erythrocytes more vulnerable to oxidative stress and has been associated 
with neonatal hyperbilirubinemia, acute hemolysis, and chronic nonspherocytic 
hemolytic anemia [21]. Some drugs should be avoided by all G6PD-deficient 
patients: these include primaquine, nitrofurantoin, and dapsone; while others like 
IV ascorbic acid, chloroquine and quinine should be used with caution.
2.3.3 Uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1)
Dolutegravir (DTG) is metabolized mainly by UGT1A1. Individuals carrying 
UGT1A1*6 and/or UGT1A1*28 polymorphs were demonstrated to be associ-
ated with high DTG trough concentrations, and that carrying UGT1A1*6 and/or 
UGT1A1*28 alleles might be a risk factor for neuropsychiatric adverse events [22]. 
HIV-1 infected patients demonstrated significant impact of UGT1A1*28 variant on 
raltegravir exposure with UGT1A1*28 carriers showing higher raltegravir plasma 
levels and lower metabolic ration when compared to UGT1A1*1/*1 carriers. This 
effect appeared to be allele-dose dependent. This pharmacokinetic effect did not 
correlate with any clinical adverse events or biological abnormalities except for 
the sensation of fatigue. Some virological failures have been associated with low 
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raltegravir exposure; hence UGT1A1*28 genotyping may still be considered as an 
interesting tool to improve raltegravir therapy particularly when risk factors for 
virological failure are present, such as high viral load at baseline, once daily regi-
men or when raltegravir is used to replace high genetic barrier drug in treatment- 
exposed patients [23].
2.3.4 Human leukocyte antigen B (HLA-B)
Abacavir-induced hypersensitivity reaction has been associated with the 
presence of the major histocompatibility complex class I allele HLA-B*5701. A 
screening test for the HLA-B*5701 allele can assist clinicians to identify patients 
who are at risk of developing a hypersensitivity reaction to abacavir. Abacavir 
hypersensitivity reaction affects 5 to 8% of patients and can be observed during 
the first 6 weeks of antiretroviral therapy [24]. Relatively high incidence of HLA-
B*1502 in many Asian populations has resulted in the FDA’s decision to recom-
mend testing for all Asians prior to initiating carbamazepine. Han Chinese who 
have the HLA-B*1502 allele are at a much increased risk of developing Stephen-
Johnsons Syndrome/ Toxic Epidermal Necrolysis (SJS/TEN) when exposed to 
carbamazepine [25].
2.3.5 Interferon Lambda 3 (Interleukin-28B)
Sofosbuvir is a potent nucleotide hepatitis C virus (HCV) Nonstructural 
protein 5B (NS5B) polymerase inhibitor that is also a P-glycoprotein (encoded by 
the ABCB1 gene) substrate. Sofosbuvir is metabolized mainly into GS-331007 in 
the liver. ABCB1 gene (3435 CT/TT and 1236 TT genotypes) are the predictors of 
GS-331007 concentrations [23]. P-glycoprotein (P-gp) removes chemical toxins 
and metabolites (including GS-331007) from cells into bile, urine and the intestinal 
lumen. Alterations in P-gp function may affect the bioavailability, distribution and 
clearance of many drugs [26]. The genetics of IL28B have played an important role 
in predicting outcome and toxicity of HCV polymerase inhibitors.
2.3.6 DNA polymerase gamma (POLG)
DNA polymerase gamma (POLG) determines the risk of sodium valproate 
induced liver toxicity. Rare mutations in POLG, which codes for the mitochondrial 
DNA polymerase gamma, cause the Alpers-Huttenlocher syndrome (AHS); a 
neuro-metabolic disorder associated with an increased risk of developing fatal 
sodium valproate hepatotoxicity [27]. Thus, sequencing the POLG gene remains 
the best diagnostic test to prevent sodium valproate-induced liver failure and 
patient death.
2.4 Clotting factors
2.4.1 Protein C, inactivator of coagulation factors Va and VIIIa (PROC, PROC1)
PROC encodes for vitamin K-dependent plasma glycoprotein called Protein C. 
The protein is cleaved to its active form by the thrombomodulin-thrombin complex. 
The activated form contains a serine protease domain and functions in degrada-
tion of the active forms of coagulation factors V and VIII. Mutations of this gene 
have been associated with thrombophilia due to protein C deficiency and recurrent 
venous thrombosis [28].
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2.4.2 SERPINC1 (Antithrombin III)
The gene SERPINC1 encodes a serine protease inhibitor named antithrombin III 
(ATIII). Antithrombin III is the most important coagulation factor inhibitor, and 
even minor changes in ATIII can significantly alter the risk of thromboembolism. 
The incidence of ATIII-inherited deficiency is relatively rare in the general popula-
tion but in patients with thromboembolism, the prevalence of ATIII deficiency 
ranges from 0.5–5%. Acquired deficiency of ATIII can be found in patients on oral 
contraceptives (progesterone). In overall, patients with the acquired type of ATIII 
deficiency are exposed to a high risk of thromboembolism, due to depletion of 
coagulation factor inhibitor critical to anticoagulation in plasma [29, 30].
2.5 Dihydropyrimidine dehydrogenase (DYPD)
The dihydropyrimidine dehydrogenase, encoded by DPYD gene, is an enzyme 
that catalyzes the rate-limiting step in fluorouracil metabolism. Genetic variations 
in the DPYD gene can lead to enzymes with reduced or no activity. Individuals who 
have at least one copy of a non-functional DPYD variant especially the DPYD*2A or 
DPYD*13, will not be able to metabolize fluorouracil at normally. As a result, these 
individuals are at risk of potentially life-threatening toxicity to fluorouracil includ-
ing bone marrow suppression and neurotoxicity. The prevalence of dihydropyrimi-
dine dehydrogenase partial deficiency is approximately 35%; although it varies in 
different populations. Complete absence of this enzyme function is often fatal with 
exposure to 5-FU chemotherapy [31].
2.6 Biomarkers inducing genetic susceptibility to diseases
Younker et al. reported a G6PD deficient 22-month-old baby who suffered 
Malignant Hyperthermia (MH). They concluded that decreased major antioxi-
dant system activity may cause susceptibility to MH [32]. Altikat et al. found that 
isoflurane has an inhibitory effect on G6PD activity; thus predisposing anaesthe-
sized patient to developing MH [33]. Malignant hyperthermia is a pharmacogenetic 
disorder in the regulation of calcium in skeletal muscles which is related to an 
uninhibited muscle hypermetabolic reaction to potent inhalation agents such as 
isoflurane.
Methemoglobin is an aberrant form of hemoglobin arising from oxidation of 
iron in the normal heme molecule from the ferrous form (Fe2+) to the ferric (Fe3+) 
form. The presence of ferric heme molecules causes a structural change in the 
hemoglobin molecule, resulting in reduced oxygen-carrying capacity and impaired 
unloading of oxygen at the tissue; resulting in left shift in the oxygen saturation 
curve causing functional anemia referred to as methemoglobinemia. While methe-
moglobinemia can be congenital and should be considered in cyanotic infants, it is 
more often an adverse medication effect, most commonly related to dapsone use. 
Dapsone most commonly causes methemoglobin, but other offending drugs include 
the local anesthetics such as lidocaine [34].
3. Conclusion
There is a correlation between individual genetic makeup and the pharmacologi-
cal response to drugs. Genetic variation plays a pivotal role in the efficacy and safety 
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best clinical practice that will eliminate the “one size fits all” approach and promote 
personalized approaches that consider individual genetic makeup in attempt to 
enhance the efficacy and safety of drugs.
4. Future aspects
The future has that the putting in place proper technologies to perform gene 
testing in clinical settings will be of great help in individualizing treatment to 
patients. However, genetic polymorphism varies between populations; therefore 
further research needs to be done on different populations so that gene testing 
technologies will focus on respective populations.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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